Foley Partner Courtenay Brinckerhoff was quoted in an article that appeared in the June 30, 2010 issue of Managing Intellectual Property titled “Federal Circuit to re-hear biotech cases post-Bilski.” Brinckerhoff discusses the Supreme Court’s decision to grant certiorari, and then vacate and remand biotech patent case Prometheus v Mayo in light of the decision issued in Bilski v. Kappos. She states that the contested patents in Prometheus should survive since the Federal Circuit has already found that they meet the machine-or-transformation test, but notes that the Bilski decision includes some troubling points for biotech and pharmaceutical patents. She adds that assessing whether a particular patent might promote or impede innovation as a way of determining patent eligibility could be a slippery slope.
People
Related News
August 5, 2025
In the News
Aaron Maguregui on Health Data Sharing Plan – 'I would expect the FTC to be heavily involved'
Foley & Lardner LLP partner Aaron Maguregui addressed a new health care data sharing initiative announced by the federal government in the Bloomberg Law article, "Digital Data-Sharing Plan Tests Limits of Health Privacy Rules."
August 1, 2025
In the News
Aaron Maguregui Assesses HIPAA Challenges as AI Advances in Health Care
Foley & Lardner LLP partner Aaron Maguregui commented in the Medical Device Network article, "AI proliferation in healthcare shines light on HIPAA shortcomings," assessing the rise and accompanying risks of artificial intelligence in health care.
August 1, 2025
In the News
Louis Lehot Assesses Figma IPO
Foley & Lardner LLP partner Louis Lehot commented on a major technology initial public offering in the Business Insider article, "Lina Kahn is taking a victory lap over the Figma IPO."